60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
August 30, 2023 07:32 ET
|
Sixty Degrees Pharmaceuticals
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
Eye Inflammation Treatment Market to Surpass US$ 888.5 Million by 2030, Says Coherent Market Insights (CMI)
March 02, 2023 09:30 ET
|
CMI
Burlingame, March 02, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global eye inflammation treatment market is estimated to be valued at US$ 564.4 Million in 2022 and is...
Antifungal Drugs Market Report will Surpass USD 25.04 Billion by 2030 at a CAGR of 4.2% Till 2030 : GreyViews
February 10, 2023 14:00 ET
|
GreyViews
Pune India, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Antifungal Drugs Market Size By Drug Class (Allylamines, Azoles, Polyenes, Echinocandins, and Others), By Route of Administration (Parenteral, Oral and...
Antifungal Drug Market Report Up to 2031: Visiongain Research Inc
January 05, 2022 09:34 ET
|
Visiongain Ltd
Visiongain has published a new report on Antifungal Drugs Market Report to 2031. Market is segmented by type (Azoles, Echinocandins, Polyenes), By Application (Aspergillosis, Dermatophytosis,...
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
August 08, 2019 16:07 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
August 07, 2019 07:30 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
July 29, 2019 07:00 ET
|
Cidara Therapeutics, Inc.
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...
Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
May 09, 2019 16:13 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
April 03, 2019 16:04 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
February 28, 2019 16:24 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...